Objective： To evaluate the efficacy and safety of irinotecan （CPT-11） plus cisplatin （DDP） in patients with small cell lung cancer （SCLC） as second-line chemotherapy. Methods： Patients received irinotecan 60 m...Objective： To evaluate the efficacy and safety of irinotecan （CPT-11） plus cisplatin （DDP） in patients with small cell lung cancer （SCLC） as second-line chemotherapy. Methods： Patients received irinotecan 60 mg/m^2 on days 1, 8, 15, and cisplatin 25 mg/m^2 on days 1-3, every 28 days one cycle. Response was evaluated every two cycles and patients were follow-up for two years or until death. Results： Among the 28 evaluable patients, there were 1 CR, 7 PR, 8 SD and 12 PD. The response rate was 28.6% （8/28）. Median time to progression （TTP） was 3.2 （0.8-5.6） months. Median survival after second-line treatment was 7.5 （1.5-31） months and overall survival was 15 （2.3-43.5） months. The most common adverse effect was hematological toxicity with 36.7% （11/30）, grades Ⅲ-Ⅳ neutroperia. Hepatic toxicity was another major side effect. Only one patient developed grade Ⅲ diarrhea. Conclusion： The combination of irinotecan and cisplatin is feasible, effective, and safe for SCLC as second-line treatment.展开更多
Health policies have played significant roles in attaining good achievements in population health improvement. This paper chronologically reviews and analyzes health-rehted parliamentary actions and law enactments in ...Health policies have played significant roles in attaining good achievements in population health improvement. This paper chronologically reviews and analyzes health-rehted parliamentary actions and law enactments in Canada. It indicates that the salient feature of the Canadian health system is that it is pubhcly financed with a single-payer, but privately run. The Canadian health system is based upon five founding principles： care must be universal （covering everyone）, portable （ among all provinces）, comprehensive （ covering all medically necessary services ）, accessible （without barriers to access hke user fees ）, and pubhdy administered（ by the government）. This paper pays special attention to what and how China can learn from Canada and what should be avoided against failures of Canadian health system, and how it might provide a new health policy base for China＇s current health reform.展开更多
文摘Objective： To evaluate the efficacy and safety of irinotecan （CPT-11） plus cisplatin （DDP） in patients with small cell lung cancer （SCLC） as second-line chemotherapy. Methods： Patients received irinotecan 60 mg/m^2 on days 1, 8, 15, and cisplatin 25 mg/m^2 on days 1-3, every 28 days one cycle. Response was evaluated every two cycles and patients were follow-up for two years or until death. Results： Among the 28 evaluable patients, there were 1 CR, 7 PR, 8 SD and 12 PD. The response rate was 28.6% （8/28）. Median time to progression （TTP） was 3.2 （0.8-5.6） months. Median survival after second-line treatment was 7.5 （1.5-31） months and overall survival was 15 （2.3-43.5） months. The most common adverse effect was hematological toxicity with 36.7% （11/30）, grades Ⅲ-Ⅳ neutroperia. Hepatic toxicity was another major side effect. Only one patient developed grade Ⅲ diarrhea. Conclusion： The combination of irinotecan and cisplatin is feasible, effective, and safe for SCLC as second-line treatment.
文摘Health policies have played significant roles in attaining good achievements in population health improvement. This paper chronologically reviews and analyzes health-rehted parliamentary actions and law enactments in Canada. It indicates that the salient feature of the Canadian health system is that it is pubhcly financed with a single-payer, but privately run. The Canadian health system is based upon five founding principles： care must be universal （covering everyone）, portable （ among all provinces）, comprehensive （ covering all medically necessary services ）, accessible （without barriers to access hke user fees ）, and pubhdy administered（ by the government）. This paper pays special attention to what and how China can learn from Canada and what should be avoided against failures of Canadian health system, and how it might provide a new health policy base for China＇s current health reform.
